STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?

In a surprising move, the U.S. Supreme Court rejected a bid by a Bristol Myers Squibb unit to reinstate a $1.2 billion award it won in a contentious patent fight with a Gilead Sciences subsidiary over the lucrative market for gene therapies.

However, the decision came just days after the Supreme Court agreed to review a very similar case involving Amgen and two other drugmakers, which essentially involves the same issue, but comes at it from a different legal perspective.

Continue to STAT+ to read the full story…

This post was originally published on this site

Leave a Reply

error: Content is protected !!
Open chat
WhatsApp Now